ARTICLE | Clinical News

Cellectar reports OS of 22.5 months in Phase I MM trial of CLR 131

August 18, 2017 7:48 PM UTC

Cellectar Biosciences Inc. (NASDAQ:CLRB) reported additional data from the first cohort of a Phase I trial in about 33 patients with relapsed or refractory multiple myeloma (MM) showing that a single dose of 12.5 mCi/m2 IV CLR 131 led to a median overall survival (OS) of 22.5 months. The cohort enrolled heavily pretreated patients.

In the second and third cohorts of the trial , single doses of 18.75 and 25 mCi/m2 IV CLR 131 led to median OS of 13.2 and 6.7 months, respectively. This quarter, Cellectar plans to present data from the trial’s fourth cohort, which is evaluating a single dose of 31.25 mCi/m2 IV CLR 131...

BCIQ Company Profiles

Cellectar Biosciences Inc.